# The KHENERGYC Study

> **NCT04846036** · PHASE2 · SUSPENDED · sponsor: **Khondrion BV** · enrollment: 24 (estimated)

## Conditions studied

- Mitochondrial Diseases
- Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
- MELAS
- Subacute Necrotizing Encephalomyelopathy

## Interventions

- **DRUG:** Sonlicromanol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04846036
- **Lead sponsor:** Khondrion BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2021-02-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 24 (ESTIMATED)
- **Why stopped:** Strategic company decision - not related to safety concerns
- **Last updated:** 2025-01-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04846036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04846036, "The KHENERGYC Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04846036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*